DrugPatentWatch Database Preview
Atorvastatin calcium - Generic Drug Details
What are the generic sources for atorvastatin calcium and what is the scope of freedom to operate?
Atorvastatin calcium
is the generic ingredient in four branded drugs marketed by Accord Hlthcare, Apotex Inc, Dr Reddys Labs Ltd, Graviti Pharms, Invagen Pharms, Lannett Co Inc, Lupin Ltd, Msn Labs Pvt Ltd, Mylan Pharms Inc, Sandoz Inc, Sciegen Pharms Inc, Sun Pharm Inds Ltd, Teva Pharms, Teva Pharms Usa, Thepharmanetwork Llc, Zydus Pharms, Pfizer, Watson Labs Teva, and Merck Sharp Dohme, and is included in twenty NDAs. Additional information is available in the individual branded drug profile pages.There are sixty-two drug master file entries for atorvastatin calcium. Sixty-three suppliers are listed for this compound.
Summary for atorvastatin calcium
| US Patents: | 0 |
| Tradenames: | 4 |
| Applicants: | 19 |
| NDAs: | 20 |
| Drug Master File Entries: | 62 |
| Suppliers / Packagers: | 63 |
| Bulk Api Vendors: | 68 |
| Clinical Trials: | 42 |
| Patent Applications: | 7,603 |
| Formulation / Manufacturing: | see details |
| Drug Sales Revenues: | Drug sales revenues for atorvastatin calcium |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for atorvastatin calcium |
| DailyMed Link: | atorvastatin calcium at DailyMed |
Recent Clinical Trials for atorvastatin calcium
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| General Hospital of Shenyang Military Region | Phase 4 |
| Jun Tao | Phase 4 |
| Sun Yat-sen University | Phase 4 |
Recent Litigation for atorvastatin calcium
Identify potential future generic entrants
District Court Litigation
| Case Name | Date |
|---|---|
| Pfizer Inc. v. Sandoz Inc. | 2010-02-09 |
| Pfizer Inc. v. Mylan Pharmaceuticals Inc. | 2010-02-03 |
| MERCK SHARP & DOHME CORP. v. MYLAN PHARMACEUTICALS INC. | 2009-12-16 |
Pharmacology for atorvastatin calcium
| Drug Class | HMG-CoA Reductase Inhibitor |
| Mechanism of Action | Hydroxymethylglutaryl-CoA Reductase Inhibitors |
Medical Subject Heading (MeSH) Categories for atorvastatin calcium
Synonyms for atorvastatin calcium
| (|AR,|AR)-2-(4-Fluorophenyl)-|A,|A-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic Acid Calcium Salt |
| (C33H34FN2O5)2.Ca |
| (R,R)-2-(4-Fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemicalcium salt |
| [R-(R*, R*)]-2-(4-fluorophenyl)-(beta), (delta)-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid, calcium salt (2:1) trihydrate |
| [R-(R*, R*)]-2-(4-fluorophenyl)-beta-, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid,calcium salt (2:1) trihydrate |
| 1108202-55-6 |
| 110862-48-1 |
| 110862-48-1 (Parent) |
| 134523-03-8 |
| 1370463-14-1 |
| 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-,-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, calcium salt (2:1), (R,R)- |
| 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-, calcium salt (2:1), (R-(R*,R*))- |
| 1H-Pyrrole-1-heptanoic acid, beta,delta-dihydroxy-2-(4-fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-, calcium salt (2:1), (R-(R*,R*))- |
| 1H-Pyrrole-1-heptanoicacid,2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-,calciumsalt(2:1),(betaR,deltaR)- |
| 2C33H34FN2O5.Ca |
| 334757-04-9 |
| 4CA-0208 |
| AC1L1TZQ |
| ACT03226 |
| AK106989 |
| AKOS015896435 |
| AM90286 |
| AN-6412 |
| AOB6343 |
| AT-3134 |
| Atorvastan |
| Atorvastatin calcium [USAN:USP] |
| Atorvastatin calcium [USAN] |
| Atorvastatin calcium anhydorous |
| Atorvastatin calcium anhydrous |
| Atorvastatin calcium salt |
| Atorvastatin Hemicalcium |
| Atorvastatin hemicalcium salt |
| BC634906 |
| BDBM50442868 |
| C0GEJ5QCSO |
| CA0146 |
| calcium (3R,5R)-7-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoate |
| calcium (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoate |
| calcium (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)pyrrol-1-yl]-3,5-dihydroxy-heptanoate |
| Calcium (betaR,deltaR)-2-(p-fluorophenyl)-beta,delta-dihydroxy-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)pyrrole-1-heptanoate (1:2) |
| calcium bis((3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-(propan-2-yl)-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoate) |
| calcium bis{(3R,5R)-7-[3-(anilinocarbonyl)-5-(4-fluorophenyl)-2-isopropyl-4-phenyl-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoate} |
| calcium;(3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoate |
| CAS-134523-03-8 |
| CHEBI:50686 |
| CHEMBL393220 |
| CI 981 |
| CI-981 |
| D00887 |
| DRG-0321 |
| DSSTox_CID_24303 |
| DSSTox_GSID_44303 |
| DSSTox_RID_80143 |
| DTXSID6044303 |
| FQCKMBLVYCEXJB-MNSAWQCASA-L |
| FT-0081085 |
| GS-3563 |
| I06-1867 |
| J-006551 |
| KB-270796 |
| Kolevas |
| KS-00000IS3 |
| Lipibec |
| Lipitor |
| Lipitor (TN) |
| Liprimar |
| LS-136974 |
| MFCD00899261 |
| MolPort-003-986-383 |
| NCGC00159458-03 |
| NCGC00159458-05 |
| NCGC00255845-01 |
| PD 134298-38A |
| Prevencor |
| Ranbaxy's Storvas |
| Rotacor |
| SC-76963 |
| SCHEMBL3832 |
| Sortis |
| Storvas |
| SW219144-1 |
| SYN3020 |
| Tahor |
| TL8000809 |
| Torvast |
| Tox21_111685 |
| Tox21_111685_1 |
| Tox21_302373 |
| Tulip |
| UNII-C0GEJ5QCSO |
| VA10343 |
| YM 548 |
| YM-548 |
US Patents and Regulatory Information for atorvastatin calcium
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dr Reddys Labs Ltd | ATORVASTATIN CALCIUM | atorvastatin calcium | TABLET;ORAL | 091650-001 | Jul 17, 2012 | AB | RX | No | No | See Pricing | See Pricing | See Pricing | |||
| Sandoz Inc | ATORVASTATIN CALCIUM | atorvastatin calcium | TABLET;ORAL | 077575-004 | May 29, 2012 | AB | RX | No | No | See Pricing | See Pricing | See Pricing | |||
| Msn Labs Pvt Ltd | ATORVASTATIN CALCIUM | atorvastatin calcium | TABLET;ORAL | 211933-004 | Feb 8, 2019 | AB | RX | No | No | See Pricing | See Pricing | See Pricing | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for atorvastatin calcium
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Pfizer | LIPITOR | atorvastatin calcium | TABLET;ORAL | 020702-004 | Apr 7, 2000 | See Pricing | See Pricing |
| Pfizer | LIPITOR | atorvastatin calcium | TABLET;ORAL | 020702-001 | Dec 17, 1996 | See Pricing | See Pricing |
| Pfizer | LIPITOR | atorvastatin calcium | TABLET;ORAL | 020702-003 | Dec 17, 1996 | See Pricing | See Pricing |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Copyright 2002-2019 thinkBiotech LLC
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
Major Patent Expirations 2019 - 2020
NCE-1 Generic Application Dates 2019 - 2020
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
Major Patent Expirations 2019 - 2020
NCE-1 Generic Application Dates 2019 - 2020
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2019, www.DrugPatentWatch.com.